This site is no longer being updated. Data are accurate as of 2 Dec 2022.

Arcturus Therapeutics Inc: LUNAR-COV19/ARCT-021

Arcturus Therapeutics Inc: LUNAR-COV19/ARCT-021

Vaccine Type: RNA

About Trial Phases

Phase 1: 2 Trials

NCT05037097
Singapore, United States of America
NCT04480957
Singapore

Phase 2: 4 Trials

NCT05037097
Singapore, United States of America
NCT04480957
Singapore
NCT04668339
Singapore, United States of America
NCT04728347
Singapore

Phase 3: 0 Trials

There are no trials for this phase.

Approvals

This vaccine is not yet approved.

Registered Trials

NCT04668339
Phase 2
Singapore, United States of America
Total Enrollment: 600
Official Trial Registration:
- NCT04668339(Opens in new tab/window)
NCT04728347
Phase 2
Singapore
Total Enrollment: 106
Official Trial Registration:
- NCT04728347(Opens in new tab/window)
NCT05037097
Phase 1/2
Singapore, United States of America
Total Enrollment: 72
Official Trial Registration:
- NCT05037097(Opens in new tab/window)
NCT04480957
Phase 1/2
Singapore
Total Enrollment: 92
Official Trial Registration:
- NCT04480957(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form